{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:22:20Z","timestamp":1789017740162,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s12325-020-01507-7","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T13:03:51Z","timestamp":1601557431000},"page":"4877-4893","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma"],"prefix":"10.1007","volume":"37","author":[{"given":"Per-Olof","family":"Thuresson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Vander Velde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palvi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,1]]},"reference":[{"issue":"9","key":"1507_CR1","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.24086","volume":"90","author":"M Al-Hamadani","year":"2015","unstructured":"Al-Hamadani M, Habermann TM, Cerhan JR, et al. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015;90(9):790\u20135. https:\/\/doi.org\/10.1002\/ajh.24086.","journal-title":"Am J Hematol"},{"key":"1507_CR2","unstructured":"SEER. Cancer stat facts: NHL\u2013diffuse large B cell lymphoma (DLBCL). In: Institute NC, editor. 2019.\nhttps:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html. Accessed June 2020."},{"issue":"9","key":"1507_CR3","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/bjc.2015.94","volume":"112","author":"A Smith","year":"2015","unstructured":"Smith A, Crouch S, Lax S, et al. Lymphoma incidence, survival and prevalence 2004\u20132014: sub-type analyses from the UK's Haematological Malignancy Research Network. Br J Cancer. 2015;112(9):1575\u201384. https:\/\/doi.org\/10.1038\/bjc.2015.94.","journal-title":"Br J Cancer"},{"key":"1507_CR4","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): B Cell Lymphomas, Version 4.2019. 2019."},{"issue":"Suppl 5","key":"1507_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"H Tilly","year":"2015","unstructured":"Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):116\u201325. https:\/\/doi.org\/10.1093\/annonc\/mdv304.","journal-title":"Ann Oncol"},{"issue":"16","key":"1507_CR6","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800\u20138. https:\/\/doi.org\/10.1182\/blood-2017-03-769620.","journal-title":"Blood"},{"issue":"10","key":"1507_CR7","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1002\/cncr.23422","volume":"112","author":"M Coleman","year":"2008","unstructured":"Coleman M, Martin P, Ruan J, et al. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring\/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer. 2008;112(10):2228\u201332. https:\/\/doi.org\/10.1002\/cncr.23422.","journal-title":"Cancer"},{"issue":"13","key":"1507_CR8","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1200\/JCO.2006.09.3146","volume":"25","author":"MJ Robertson","year":"2007","unstructured":"Robertson MJ, Kahl BS, Vose JM, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B cell lymphoma. J Clin Oncol. 2007;25(13):1741\u20136. https:\/\/doi.org\/10.1200\/JCO.2006.09.3146.","journal-title":"J Clin Oncol"},{"issue":"30","key":"1507_CR9","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","volume":"26","author":"PH Wiernik","year":"2008","unstructured":"Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008;26(30):4952\u20137. https:\/\/doi.org\/10.1200\/JCO.2007.15.3429.","journal-title":"J Clin Oncol"},{"issue":"35","key":"1507_CR10","doi-asserted-by":"publisher","first-page":"3285","DOI":"10.18632\/oncotarget.26904","volume":"10","author":"L Wang","year":"2019","unstructured":"Wang L, Lam H, Shou Y, et al. Meta-analytical methods for estimating outcomes from overall response rate in patients with relapsed\/refractory diffuse large B cell lymphoma. Oncotarget. 2019;10(35):3285\u201393. https:\/\/doi.org\/10.18632\/oncotarget.26904.","journal-title":"Oncotarget"},{"issue":"Suppl 1","key":"1507_CR11","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1182\/blood-2018-99-118551","volume":"132","author":"LH Sehn","year":"2018","unstructured":"Sehn LH, Herrera AF, Matasar MJ, et al. Polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G) in relapsed\/refractory (R\/R) diffuse large B cell lymphoma (DLBCL): updated results of a phase (Ph) Ib\/II study. Blood. 2018;132(Suppl 1):1683. https:\/\/doi.org\/10.1182\/blood-2018-99-118551.","journal-title":"Blood"},{"key":"1507_CR12","unstructured":"Polivy USPI. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761121s000lbl.pdf. Accessed June 2020."},{"key":"1507_CR13","unstructured":"SCT: Polivy SmPC. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/polivy-epar-product-information_en.pdf. Accessed June 2020."},{"key":"1507_CR14","unstructured":"Genentech Inc. POLIVY\u2122 (polatuzumab vedotin-piiq) for injection, for intravenous use. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761121s000lbl.pdf.\nAccessed June 2020."},{"issue":"7","key":"1507_CR15","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1080\/10428194.2018.1564828","volume":"60","author":"GA Salles","year":"2019","unstructured":"Salles GA, Pettengell R, Cordoba R, et al. Treatment of aggressive B cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review. Leuk Lymphoma. 2019;60(7):1610\u201325. https:\/\/doi.org\/10.1080\/10428194.2018.1564828.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"1507_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jech.52.6.377","volume":"52","author":"SH Downs","year":"1998","unstructured":"Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377\u201384. https:\/\/doi.org\/10.1136\/jech.52.6.377.","journal-title":"J Epidemiol Community Health"},{"issue":"1","key":"1507_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4103\/0973-1482.63572","volume":"6","author":"M Aribi","year":"2010","unstructured":"Aribi M, Mesli N, Remla N, et al. Gemcitabine and treatment of diffuse large B cell lymphoma in relapsed or refractory elderly patients: a prospective randomized trial in Algeria. J Cancer Res Ther. 2010;6(1):41\u20136. https:\/\/doi.org\/10.4103\/0973-1482.63572.","journal-title":"J Cancer Res Ther"},{"issue":"2","key":"1507_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3816\/CLML.2010.n.017","volume":"10","author":"A Aviles","year":"2010","unstructured":"Aviles A, Neri N, Huerta-Guzman J, et al. ESHAP versus rituximab-ESHAP in frail patients with refractory diffuse large B cell lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10(2):125\u20138. https:\/\/doi.org\/10.3816\/CLML.2010.n.017.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"15","key":"1507_CR19","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1158\/1078-0432.CCR-16-2818","volume":"23","author":"MS Czuczman","year":"2017","unstructured":"Czuczman MS, Trneny M, Davies A, et al. A Phase 2\/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator's choice in patients with relapsed or refractory diffuse large B Cell lymphoma. Clin Cancer Res. 2017;23(15):4127\u201337. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2818.","journal-title":"Clin Cancer Res"},{"issue":"15_Suppl","key":"1507_CR20","doi-asserted-by":"publisher","first-page":"8529","DOI":"10.1200\/jco.2014.32.15_suppl.8529","volume":"32","author":"NH Dang","year":"2014","unstructured":"Dang NH, Ogura M, Castaigne S, et al. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL). J Clin Oncol. 2014;32(15_Suppl):8529. https:\/\/doi.org\/10.1200\/jco.2014.32.15_suppl.8529.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1507_CR21","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/bjh.14101","volume":"174","author":"R Pettengell","year":"2016","unstructured":"Pettengell R, Sebban C, Zinzani PL, et al. Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial. Br J Haematol. 2016;174(5):692\u20139. https:\/\/doi.org\/10.1111\/bjh.14101.","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"1507_CR22","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1182\/blood-2018-99-112455","volume":"132","author":"GA Salles","year":"2018","unstructured":"Salles GA, Jurczak W, Andorsky DJ, et al. Results of a Phase 3 randomised multicenter study comparing pixantrone + rituximab with gemcitabine + rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation. Blood. 2018;132(Suppl 1):4189. https:\/\/doi.org\/10.1182\/blood-2018-99-112455.","journal-title":"Blood"},{"issue":"8","key":"1507_CR23","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/annonc\/mdm133","volume":"18","author":"T El Gnaoui","year":"2007","unstructured":"El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol. 2007;18(8):1363\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdm133.","journal-title":"Ann Oncol"},{"issue":"4","key":"1507_CR24","doi-asserted-by":"publisher","first-page":"857","DOI":"10.4103\/0973-1482.151418","volume":"11","author":"KC Lakshmaiah","year":"2015","unstructured":"Lakshmaiah KC, Rachan Shetty KS, Sathyanarayanan V, et al. Lenalidomide in relapsed refractory non-Hodgkin's lymphoma: an Indian perspective. J Cancer Res Ther. 2015;11(4):857\u201361. https:\/\/doi.org\/10.4103\/0973-1482.151418.","journal-title":"J Cancer Res Ther"},{"issue":"2","key":"1507_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1600-0609.2007.00996.x","volume":"80","author":"A Lopez","year":"2008","unstructured":"Lopez A, Gutierrez A, Palacios A, et al. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory\/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol. 2008;80(2):127\u201332. https:\/\/doi.org\/10.1111\/j.1600-0609.2007.00996.x.","journal-title":"Eur J Haematol"},{"issue":"11","key":"1507_CR26","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.3324\/haematol.2013.090597","volume":"98","author":"N Mounier","year":"2013","unstructured":"Mounier N, El Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory\/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica. 2013;98(11):1726\u201331. https:\/\/doi.org\/10.3324\/haematol.2013.090597.","journal-title":"Haematologica"},{"issue":"26","key":"1507_CR27","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"issue":"17","key":"1507_CR28","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1200\/JCO.2012.46.5203","volume":"31","author":"K Ohmachi","year":"2013","unstructured":"Ohmachi K, Niitsu N, Uchida T, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2013;31(17):2103\u20139. https:\/\/doi.org\/10.1200\/JCO.2012.46.5203.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1507_CR29","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/j.1600-0609.2005.00482.x","volume":"75","author":"ES Papageorgiou","year":"2005","unstructured":"Papageorgiou ES, Tsirigotis P, Dimopoulos M, et al. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group. Eur J Haematol. 2005;75(2):124\u20139. https:\/\/doi.org\/10.1111\/j.1600-0609.2005.00482.x.","journal-title":"Eur J Haematol"},{"issue":"Suppl 1","key":"1507_CR30","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1182\/blood-2018-99-115252","volume":"132","author":"SJ Schuster","year":"2018","unstructured":"Schuster SJ, Bishop MR, Tam C, et al. Sustained disease control for adult patients with relapsed or refractory diffuse large B-Cell lymphoma: an updated analysis of juliet, a global pivotal phase 2 trial of tisagenlecleucel. Blood. 2018;132(Suppl 1):1684. https:\/\/doi.org\/10.1182\/blood-2018-99-115252.","journal-title":"Blood"},{"issue":"26","key":"1507_CR31","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545\u201354. https:\/\/doi.org\/10.1056\/NEJMoa1708566.","journal-title":"N Engl J Med"},{"issue":"3","key":"1507_CR32","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00277-013-1879-x","volume":"93","author":"JL Vacirca","year":"2014","unstructured":"Vacirca JL, Acs PI, Tabbara IA, et al. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Ann Hematol. 2014;93(3):403\u20139. https:\/\/doi.org\/10.1007\/s00277-013-1879-x.","journal-title":"Ann Hematol"},{"issue":"7","key":"1507_CR33","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","volume":"22","author":"TE Witzig","year":"2011","unstructured":"Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011;22(7):1622\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdq626.","journal-title":"Ann Oncol"},{"issue":"6","key":"1507_CR34","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.clml.2011.02.001","volume":"11","author":"PL Zinzani","year":"2011","unstructured":"Zinzani PL, Pellegrini C, Gandolfi L, et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk. 2011;11(6):462\u20136. https:\/\/doi.org\/10.1016\/j.clml.2011.02.001.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"1507_CR35","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/S1470-2045(12)70212-7","volume":"13","author":"R Pettengell","year":"2012","unstructured":"Pettengell R, Coiffier B, Narayanan G, et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2012;13(7):696\u2013706. https:\/\/doi.org\/10.1016\/S1470-2045(12)70212-7.","journal-title":"Lancet Oncol"},{"issue":"31","key":"1507_CR36","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","volume":"32","author":"M Crump","year":"2014","unstructured":"Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32(31):3490\u20136. https:\/\/doi.org\/10.1200\/JCO.2013.53.9593.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1507_CR37","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.3109\/10428194.2015.1007504","volume":"56","author":"L Fayad","year":"2015","unstructured":"Fayad L, Ansell SM, Advani R, et al. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leuk Lymphoma. 2015;56(9):2569\u201378. https:\/\/doi.org\/10.3109\/10428194.2015.1007504.","journal-title":"Leuk Lymphoma"},{"issue":"27","key":"1507_CR38","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184\u201390. https:\/\/doi.org\/10.1200\/JCO.2010.28.1618.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1507_CR39","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1080\/10428194.2016.1256481","volume":"58","author":"NL Bartlett","year":"2017","unstructured":"Bartlett NL, Smith MR, Siddiqi T, et al. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Leuk Lymphoma. 2017;58(7):1607\u201316. https:\/\/doi.org\/10.1080\/10428194.2016.1256481.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"1507_CR40","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol. 2017;35(8):826\u201333. https:\/\/doi.org\/10.1200\/JCO.2016.70.4320.","journal-title":"J Clin Oncol"},{"key":"1507_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802094229","author":"S Gumenyuk","year":"2016","unstructured":"Gumenyuk S, Marchesi F, Borza PA, et al. Salvage treatment with R-IEV (rituximab, ifosfamide, epirubicin, etoposide) and autologous stem cell transplant for relapsed\/refractory diffuse large B-cell lymphoma. Haematologica. 2016. https:\/\/doi.org\/10.1080\/10428190802094229.","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"1507_CR42","doi-asserted-by":"publisher","first-page":"i11","DOI":"10.1093\/annonc\/mdg703","volume":"14","author":"MS Hertzberg","year":"2003","unstructured":"Hertzberg MS, Crombie C, Benson W, et al. Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease. Ann Oncol. 2003;14(Suppl 1):i11\u2013i16. https:\/\/doi.org\/10.1093\/annonc\/mdg703.","journal-title":"Ann Oncol"},{"issue":"9","key":"1507_CR43","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","volume":"125","author":"ED Jacobsen","year":"2015","unstructured":"Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394\u2013402. https:\/\/doi.org\/10.1182\/blood-2014-09-598763.","journal-title":"Blood"},{"issue":"3","key":"1507_CR44","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1600-0609.2004.00294.x","volume":"73","author":"M Jerkeman","year":"2004","unstructured":"Jerkeman M, Leppa S, Kvaloy S, et al. ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma\u2013the Nordic Lymphoma Group experience. Eur J Haematol. 2004;73(3):179\u201382. https:\/\/doi.org\/10.1111\/j.1600-0609.2004.00294.x.","journal-title":"Eur J Haematol"},{"issue":"3","key":"1507_CR45","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/annonc\/mdh093","volume":"15","author":"M Jermann","year":"2004","unstructured":"Jermann M, Jost LM, Taverna C, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol. 2004;15(3):511\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdh093.","journal-title":"Ann Oncol"},{"issue":"5","key":"1507_CR46","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1093\/annonc\/mdy056","volume":"29","author":"W Jurczak","year":"2018","unstructured":"Jurczak W, Zinzani PL, Gaidano G, et al. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Ann Oncol. 2018;29(5):1266\u201372. https:\/\/doi.org\/10.1093\/annonc\/mdy056.","journal-title":"Ann Oncol"},{"issue":"12","key":"1507_CR47","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.3324\/haematol.13440","volume":"93","author":"A Martin","year":"2008","unstructured":"Martin A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL\/TAMO study. Haematologica. 2008;93(12):1829\u201336. https:\/\/doi.org\/10.3324\/haematol.13440.","journal-title":"Haematologica"},{"key":"1507_CR48","first-page":"28","volume":"64","author":"SJ Proctor","year":"2001","unstructured":"Proctor SJ, Taylor PR, Angus B, et al. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed\/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. Eur J Haematol Suppl. 2001;64:28\u2013322.","journal-title":"Eur J Haematol Suppl"},{"issue":"5","key":"1507_CR49","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/annonc\/mdh176","volume":"15","author":"K Tobinai","year":"2004","unstructured":"Tobinai K, Igarashi T, Itoh K, et al. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol. 2004;15(5):821\u201330. https:\/\/doi.org\/10.1093\/annonc\/mdh176.","journal-title":"Ann Oncol"},{"issue":"9","key":"1507_CR50","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1038\/leu.2013.95","volume":"27","author":"M Wang","year":"2013","unstructured":"Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013;27(9):1902\u20139. https:\/\/doi.org\/10.1038\/leu.2013.95.","journal-title":"Leukemia"},{"issue":"4","key":"1507_CR51","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3816\/clm.2001.n.003","volume":"1","author":"DD Wilder","year":"2001","unstructured":"Wilder DD, Ogden JL, Jain VK. A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma. Clin Lymphoma. 2001;1(4):285\u201392. https:\/\/doi.org\/10.3816\/clm.2001.n.003.","journal-title":"Clin Lymphoma"},{"issue":"Suppl 1","key":"1507_CR52","doi-asserted-by":"publisher","first-page":"i5","DOI":"10.1093\/annonc\/mdg702","volume":"14","author":"AD Zelenetz","year":"2003","unstructured":"Zelenetz AD, Hamlin P, Kewalramani T, et al. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. 2003;14(Suppl 1):i5\u201310. https:\/\/doi.org\/10.1093\/annonc\/mdg702.","journal-title":"Ann Oncol"},{"key":"1507_CR53","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/bjh.14820","volume":"182","author":"NHOM Dang","year":"2018","unstructured":"Dang NHOM, Castaigne S, Fayad LE, et al. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2018;182:579\u2013609. https:\/\/doi.org\/10.1111\/bjh.14820.","journal-title":"Br J Haematol"},{"key":"1507_CR54","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188\u201395. https:\/\/doi.org\/10.1182\/blood-2014-05-552729.","journal-title":"Blood"},{"key":"1507_CR55","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","volume":"11","author":"D Porter","year":"2018","unstructured":"Porter D, Frey N, Wood PA, et al. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018;11:35. https:\/\/doi.org\/10.1186\/s13045-018-0571-y.","journal-title":"J Hematol Oncol"},{"key":"1507_CR56","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"1507_CR57","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2217\/cer-2019-0062","volume":"8","author":"R Ionescu-Ittu","year":"2019","unstructured":"Ionescu-Ittu R, Shang A, Velde NV, et al. Second-line rituximab-bendamustine versus rituximab-gemcitabine-oxaliplatin in diffuse large B-cell lymphoma in the real world. J Comp Eff Res. 2019;8(13):1067\u201375. https:\/\/doi.org\/10.2217\/cer-2019-0062.","journal-title":"J Comp Eff Res"},{"issue":"27","key":"1507_CR58","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1507_CR59","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244. https:\/\/doi.org\/10.1200\/JCO.1999.17.4.1244.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1507_CR60","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579\u201386. https:\/\/doi.org\/10.1200\/JCO.2006.09.2403.","journal-title":"J Clin Oncol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01507-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01507-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01507-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T01:01:17Z","timestamp":1633050077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01507-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1507"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01507-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]},"assertion":[{"value":"19 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}